Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | MAOA | P21397 | 1/20 | 0.57 |
| ▸ | MAOB | P27338 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 11/20 | 0.50 |
| ▸ | CA2 | P00918 | 11/20 | 0.50 |
| ▸ | CA12 | O43570 | 7/20 | 0.50 |
| ▸ | CA9 | Q16790 | 7/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | STK17B | O94768 | 1/20 | 0.42 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1557954 | 0.95 | TDP1 (0.56) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL7097924 | 0.95 | TDP1 (0.65) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL16358704 | 0.92 | TDP1 (0.53) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL7095175 | 0.91 | TDP1 (0.55) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL7096665 | 0.91 | TDP1 (0.55) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL30980540 | 0.89 | TDP1 (0.61) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL14738985 | 0.89 | TDP1 (0.61) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL15612944 | 0.89 | TDP1 (0.55) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL21320306 | 0.87 | TDP1 (0.59) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL19591067 | 0.86 | CA12 (0.58) | TDP1MEN1GAAKMT2AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4651901-A1 | CYCLING LYSOSOMAL TARGETING ANTIBODY CONJUGATES | Lycia Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4651902-A2 | ASGPR BINDING COMPOUNDS AND CONJUGATES | Lycia Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| WO-2025035040-A1 | LYSOSOMAL TARGETING BIFUNCTIONAL MOLECULES FOR DEGRADATION OF MUSCLE-SPECIFIC KINASE AUTOANTIBODIES | LYCIA THERAPEUTICS, INC. (US) | 2025-02-13 | — | — | WO | disclosed |
| WO-2024155747-A2 | ASGPR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. (US) | 2024-07-25 | — | — | WO | disclosed |
| US-20210003506-A1 | FLUORESCENCE SPECTRAL SHAPE ANALYSIS FOR ANALYTE RECOGNITION | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-01-07 | — | — | US | disclosed |
| WO-2016192528-A1 | Trimaleimide Linkers and Uses Thereof | NEWBIO THERAPEUTICS, INC. (CN) | 2016-12-08 | — | — | WO | disclosed |
| US-9302012-B2 | Anti-bacterial siderophore-aminopenicillin conjugates | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2016-04-05 | — | — | US | disclosed |
| US-20130281424-A1 | ANTI-BACTERIAL SIDEROPHORE-AMINOPENICILLIN CONJUGATES | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2013-10-24 | — | — | US | disclosed |
| US-8475768-B2 | Paramagnetic chelates thereof and their use as contrast agents in magnetic resonance imaging (MRI) | GE HEALTHCARE AS (NO) | 2013-07-02 | — | — | US | disclosed |
| US-8158804-B2 | Chelating agents | GE HEALTHCARE AS (NO) | 2012-04-17 | — | — | US | disclosed |
| US-8158804-B2 | Chelating agents | GE HEALTHCARE AS (NO) | 2012-04-17 | — | — | US | disclosed |
| US-20100056787-A1 | CHELATING AGENTS | GE HEALTHCARE AS (NO) | 2010-03-04 | — | — | US | disclosed |
| US-20100056787-A1 | CHELATING AGENTS | GE HEALTHCARE AS (NO) | 2010-03-04 | — | — | US | disclosed |
| WO-2008085064-A2 | HYDROXYPYRIDINONE CHELATING AGENTS, THEIR METAL COMPLEXES AND THEIR USE AS MRI CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281424-A1 | ANTI-BACTERIAL SIDEROPHORE-AMINOPENICILLIN CONJUGATES | SLC7A1, SLC7A5, SLC40A1 | TDP1 4294/4885MEN1 4667/4885GAA 395/4885 |
| US-20100056787-A1 | CHELATING AGENTS | SLC39A3, SLC40A1, TFRC | TDP1 3059/4885MEN1 249/4885GAA 411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.